Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,142 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00112840 | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT03136627 | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | completed | Phase 1 / Phase 2 | 28 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT00730639 | A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies(MDX1106-03) | completed | Phase 1 | 395 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01472081 | Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | completed | Phase 1 | 194 | Bristol-Myers SquibbINDUSTRY | 2 | Dec 2, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT01358721 | Phase I Biomarker Study (BMS-936558) | completed | Phase 1 | 119 | Bristol-Myers SquibbINDUSTRY | 3 | Oct 28, 2021 | clinicaltrials |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | completed | Phase 1 | 502 | Corvus Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 30, 2021 | clinicaltrials |
| NCT04496089 | Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC(ZIRDAC-JP) | completed | Phase 1 | 6 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Aug 24, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT01826877 | Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer | completed | Phase 1 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT02989714 | Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer | completed | Phase 1 / Phase 2 | 13 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT02118337 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 97 | MedImmune LLCINDUSTRY | 6 | Jun 1, 2021 | clinicaltrials |
| NCT00121251 | Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT00258687 | Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT00715182 | A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer | completed | Phase 1 | 87 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 | clinicaltrials |
| NCT01152801 | Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer | completed | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01482156 | Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 21, 2020 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02077933 | Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | completed | Phase 1 | 79 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 8, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00004880 | Vaccine Therapy in Treating Patients With Advanced Kidney Cancer | completed | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT02575222 | Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 12, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT01510119 | Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT02053220 | Mechanism of Action Trial of ColoAd1(MOA) | completed | Phase 1 | 17 | Akamis BioINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02406521 | Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets | completed | Phase 1 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02014636 | Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) | completed | Phase 1 | 42 | Novartis PharmaceuticalsINDUSTRY | 2 | Mar 3, 2020 | clinicaltrials |
| NCT01497444 | Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 1 | 24 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT01550367 | Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) | completed | Phase 1 / Phase 2 | 30 | Leonard ApplemanOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT00304460 | Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer | completed | Phase 1 | 138 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT04180774 | Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer | completed | Phase 1 / Phase 2 | 80 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT01021059 | A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00923169 | Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 29, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01184326 | Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT02843607 | Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02300610 | Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | completed | Phase 1 | 10 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT00005851 | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT01844947 | Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract(VINSOR) | completed | Phase 1 | 22 | Dr Anders UllénOTHER | 2 | Apr 26, 2019 | clinicaltrials |
| NCT02145559 | A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors | completed | Phase 1 | 24 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03427476 | CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma | completed | Phase 1 | 4 | Cancer Targeted TechnologyINDUSTRY | 1 | Apr 22, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Feb 1, 2022source: clinicaltrials